novo glp-1 and Lilly shift strategy abroad: US may be next Novo Nordisk's New Oral GLP‑1

References: [1] FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes

However, in patients with established atherosclerotic cardiovascular disease, high cardiovascular risk, or chronic kidney disease, they are now recommended as first-line therapy [22]

This gap underscores the urgent need for GMP manufacturing standardization and large-animal pharmacokinetic bridging studies before investigational new drug applications can be credibly submitted

NICE guidelines (NG28) recommend specific injectable GLP-1 receptor agonists for type 2 diabetes management in appropriate clinical contexts

The Current Avon Brochure Avon Brochure Campaign 16 is Active from 7/29/26 - 8/11/26